Seeking Alpha

The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed...

The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed acquisition of Cephalon would have been anti-competitive for several generic drugs. The order requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals (PRX -0.6%), and  allow PRX to sell a generic version of Cephalon's narcolepsy drug Provigil in 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs